New Test for Zika OKed

The US Food and Drug Administration gave emergency approval for a combination diagnostic that can distinguish between Zika, dengue, and chikungunya infections.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, MADPRIMECurrent PCR-based Zika tests can’t rule out infections with dengue or chikungunya viruses—infections that cause similar symptoms and are also transmitted by Aedes mosquitoes. Last week (March 18), the US Food and Drug Administration (FDA) granted the US Centers for Disease Control and Prevention (CDC) approval to start using a three-in-one assay that screens for all three viruses simultaneously.

“This [emergency use authorization] will potentially allow CDC to more rapidly perform testing to detect acute Zika virus infection,” the CDC said in a statement.

The test won’t be available in hospitals or doctors offices, but will be used in a designated network of laboratories that assists in public health emergencies.

Last month, the FDA granted emergency use authorization (EUA) for these labs to use a diagnostic that can detect infections through antibodies in the patient’s blood weeks after the virus has been cleared. However, the test cannot rule out the possibility that a positive result was caused by dengue, and research labs and biotech firms are working to develop a more-specific antibody assay.

“As there are no commercially available diagnostic tests cleared or approved ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies